doxo-emch and Bone-Neoplasms

Supramolecular nanodrug assembly driven by supramolecular chemistry is becoming a powerful strategy for medication. The potential of engineered proteins as building blocks for nanoformulations is rarely investigated. Here, we developed a new generation of recombinant protein-based nanodrug carriers, which is very efficient for loading and delivering the hydrophobic prodrug aldoxorubicin. Significantly enhanced anti-tumor effects in osteosarcoma (OS) models were observed. The half-life of the nanodrug reached almost two days and the corresponding bioavailability increased by 17-fold. This is significantly superior to other drug counterparts, empowering long-acting OS treatment scenarios. Importantly, off-target side effects of the prodrug, including cardiotoxicity and lung-metastasis, were greatly mitigated with our medication. Thus, our assembly strategy enables the customized design of advanced nanodelivery systems employing broader biomaterial building blocks for cancer therapy.

Topics: Animals; Antineoplastic Agents; Biological Availability; Bone Neoplasms; Doxorubicin; Drug Carriers; Humans; Hydrazones; Hydrophobic and Hydrophilic Interactions; Macromolecular Substances; Mice; Mice, Nude; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Osteosarcoma; Particle Size; Prodrugs; Recombinant Proteins